Exhibit 99.1


 Preclinical  Phase 1  GASTRIC, ESOPHAGEAL & PANCREATICt  (CLAUDIN 18.2)  Auto logous NCT04467853  RRMM (BCMA)  LEGEND-2t  Auto logous NCT03090659  IGlobal  IUS I  China  Phase 2  MMt  (BCMA)  Al logeneic - CAR-NK NCT05498545  MMt  (BCMA)  A llogeneic - CAR-yo T NCT05376345  NHLt /ALLt  (CD19 X CD20 X CD22}t  Auto logous NCT05318963 NCT05292898  Hect  (GPC3)  Auto logous NCT05352542  The safety and efficacy of the agents and/or uses under investigation have not been established.  There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list.  *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. tPhase 1 llT in China.  :t:IND applications have been cleared by the U.S. FDA.  ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCMA, B-cell maturation antigen; DLL3, delta-like ligand 3; GPC3, glypican-3; GCC, guanylyl cyclase C; HCC, hepatocellular carcinoma; llT, investigator-initiated trial; MM, multiple myeloma; ND, newly diagnosed; NHL, non-Hodgkin lymphoma; NSCLC, non small cell lung cancer; RRMM, relapsed or refractory multiple myeloma; SCLC, small cell lung cancer.  Phase 3  RRMM (BCMA)*  1-3 Prior Lines CARTITUDE-4  Autologous NCT04181827  NDMM (BCMA)*  Transplant Not Intended CARTITUDE-5  Autologous NCT04923893  NDMM (BCMA)*  Transplant Eligible CARTITUDE-6  Autologous NCT05257083  GASTRIC, ESOPHAGEAL & PANCREATIC*  (CLAUDIN 18.2)  Autologous  SCLC*  (DLL3)  Autologous  NSCLC  (GPC3)  Auto logous  COLORECTAL  (GCC)  A utologous  AML  (CLL 1/CD33 )  A llogeneic  RRMM (BCMA)*  CARTIFAN-1  Auto logous NCT03758417  RRMM (BCMA)*  CARTITUDE-1  Auto logous NCT03548207  MM (BCMA)*  CARTITUDE-2  Auto logous NCT04133636